Clinical trial NCT00985114: Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
Official title: An Open Label, Randomized, Controlled Study of a Second Generation EndoBarrier™ Liner vs. Diet Control for the Treatment of Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type II Diabetes
Keywords: Type II Diabetes
Obesity
Lead sponsor: Morphic Medical Inc.
Sponsor class: INDUSTRY
First posted: 2009-09-28
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of a second generation EndoBarrier Liner compared to a study diet to treat Subjects with Type 2 Diabetes.

This is a randomized, controlled study which will enroll approximately 70 Subjects with Type 2 Diabetes. Randomization will be one to one with approximately 35 EndoBarrier device Subjects and approximately 35 study diet Subjects. Subjects randomized as diet Subjects will be offered the EndoBarrier device after 12 months on study at the investigator's discretion if treatment of the device subjects indicates adequate efficacy. This study will be conducted at three (3) investigational sites.

The primary efficacy endpoint is:

* Assessment of the percent (%) of Subjects who achieve a ≥ 0.5% reduction in HbA1C at 24 weeks or last visit from baseline between the two groups.

Secondary endpoints are:

* Percent (%) of Subjects who achieve a HbA1C of 7.0% or lower at week 24 or last visit from baseline.
* Percent (%) of Subjects who have their diabetic medication(s) dosage decreased or discontinued at week 24 or last visit from baseline.
* Percent (%) of Subjects who achieve a decrease in post-prandial excursions as evidenced by challenge to a standardized meal tolerance test (MTT) at week 24 or last visit from baseline.
* Assessment of absolute weight loss (Kg) at week 24 or last visit from baseline.
* Percent (%) of Subjects who maintain a HbA1c lower than their baseline assessment at 12 months.
* Compare physical component summary (PCS), mental component summary (MCS) and quality adjusted life years (QALYs)via analysis of the SF-36v2 QOL.

Detailed description: Utilization of the EndoBarrier Gastrointestinal Liner in obese subjects with T2DM demonstrated an acceptable safety profile with clinically significant improvements in glycemic control and body weight when compared to a similar diet controlled group of subjects.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years and \< 65 years
* Male or Female
* Subjects with Type 2 Diabetes who have been treated for ≤10 years
* BMI\> 30 - \< 50
* Subjects with an HbA1c level \> 7.5 and ≤ 10.0%
* Subjects taking a combination of metformin and sulfonylureas and/or insulin (other than pre-mixed long and short acting insulins, ie. NovoMix 30)
* Patients willing to comply with study requirements
* Patients who have signed an informed consent form

Exclusion Criteria:

* Subjects taking oral medications to control their diabetes other than sulfonylureas and metformin
* Subjects diagnosed with Type 1 Diabetes Mellitus or having a history of ketoacidosis
* Subjects on insulin \> 10 years
* Subjects requiring insulin \> 70 units per day
* Subjects on pre-mixed insulin (ie. NovoMix 30)

Primary outcomes:
measure: Percent (%) of Subjects Who Achieve a ≥ 0.5% Reduction in HbA1C at 24 Weeks or Last Visit From Baseline.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Arnhem
country: Netherlands
facility: Ziekenhuis Rijnstate Arnhem
city: Heerlen
country: Netherlands
facility: Medisch Centrum Parkstad
city: Maastricht
country: Netherlands
facility: University Hospital Maastricht
Study officials:
affiliation: University Hospital Masstricht
name: Jan Willem Greve, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, le Roux CW, Bouvy ND, Greve JW. Impact of Duodenal-Jejunal Exclusion on Satiety Hormones. Obes Surg. 2016 Mar;26(3):672-8. doi: 10.1007/s11695-015-1889-y.
citation: Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014 Dec;260(6):984-92. doi: 10.1097/SLA.0000000000000794.
citation: de Jonge C, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND, Greve JW. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013 Nov;11(11):1517-20. doi: 10.1016/j.cgh.2013.07.029. Epub 2013 Aug 3.